Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

ONO PHARMACEUTICAL : ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients (20.2KB)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2012 | 07:58am CET

April 17, 2012

ONO PHARMACEUTICAL CO., LTD.

President and Representative Director: Gyo Sagara,

Code No.: 4528 at the 1st section of the Tokyo / Osaka Stock Exchange

INQUIRIES: Kinya Morimoto, Executive Officer, Director, Corporate Communications

ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients

Ono Pharmaceutical Co., Ltd. announced today that the global Phase II study (DreaMS*) of ONO-4641 in development for the indication of multiple sclerosis (MS) was completed and met the primary endpoint.
The study was a double-blind placebo-controlled study conducted in 11 countries including North America, Europe and Japan in patients with relapsing-remitting multiple sclerosis. A total of 407 patients between the ages of 18 and 55 with relapsing-remitting MS were randomized to receive placebo or one of 3 active doses of ONO-4641 once daily for 26 weeks.
Patients were included in the study if they had two or more relapses in the two years prior to the study, one or more relapses within the year prior to the study or one or more new MS-related brain lesions, also known as Gd-enhancing lesions, detected on MRI within three months prior to the study. For the primary endpoint of the study, MRIs were performed every four weeks from 10 to 26 weeks, 5 times.
At the end of the study, patients taking 0.05, 0.10, or 0.15 mg of ONO-4641 had 82 percent, 92 percent and 77 percent fewer Gd-enhancing brain lesions (all p<0.0001), respectively, compared to placebo.
Adverse events appeared to be generally dose related. Of note was a slower heartbeat and atrioventricular blocks associated with the initiation of treatment, which were asymptomatic, transient and did not require ONO-4641 discontinuation. Other notable adverse events included liver enzyme elevations. In addition, Grade 4 lymphopenia, which is an abnormally low level of lymphocytes in the blood, occurred in 4 percent of patients receiving the 0.15 mg dose of ONO-4641 and in 1 percent of those receiving the 0.10 mg dose.
Detailed data will be presented at the American Academy of Neurology's 64th Annual Meeting in
New Orleans April 21 to April 28, 2012.
Ono has granted Merck KGaA, Darmstadt, Germany, an exclusive license for development and commercialization of ONO-4641 in countries around the world except Japan, Korea and Taiwan under the agreement entered into October, 2011.

* DreaMS: Drug Research EvaluAtion for Multiple Sclerosis

<Reference> About ONO-4641
ONO-4641 is a sphingosine-1-phosphate (S1P) receptor agonist which keeps lymphocytes in lymph nodes and thereby inhibits the infiltration of lymphocytes into lesions. The compound is therefore expected to be a drug for the treatment of auto-immune diseases such as multiple sclerosis, which is regarded as an intractable disease.

About Multiple Sclerosis

Multiple sclerosis is a chronic neurological disorder accompanying by diverse and severe neurological symptoms such as paralysis and numbness of limbs, gait disorders, visual disorders, and dysuria. Although there are no specific factors known to be responsible for the onset and relapses of the disease, it is thought to be an autoimmune disease that, because of some triggers, one's own body is improperly recognized as foreign and is attacked by lymphocytes, which have an essential role in the immune system for protection from foreign substances such as viruses and bacteria. Most patients are diagnosed between the ages of 20 and 40, and women tend to suffer disproportionately more from this disease compared to men. In Japan, around 14,500 people suffer from this disorder. It is estimated that there are at least 350,000 MS patients in the US and about 2.5 million globally.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONO PHARMACEUTICAL CO., LT
02/15 LAUNCH OF PARSABIV® INTRAVENOUS INJE : Etelcalcetide Hydrochloride), a Calcimime..
02/08 ONO PHARMACEUTICAL : U.S. Food and Drug Administration Approves Parsabiv™ ..
02/06 ONO PHARMACEUTICAL : Certain Media Coverage Related to ONO Reported on February ..
02/03 ONO PHARMACEUTICAL : Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivo..
02/02 Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and Lice..
01/24 BRISTOL-MYERS SQUIBB CO (NYSE : BMY) To Share In Sales Of Merck & Co., Inc. (NYS..
01/21 ONO PHARMACEUTICAL : and Bristol-Myers Squibb Enter Settlement and License Agree..
01/20 ONO PHARMACEUTICAL : Bristol-Myers Squibb Provides Regulatory Update in First-li..
01/20 ONO PHARMACEUTICAL : Data with OPDIVO® (nivolumab) Intravenous Infusion in Gastr..
2016 ONO PHARMACEUTICAL : Submits Supplemental Application of OPDIVO® (Nivolumab) for..
More news
Sector news : Generic Pharmaceuticals
02/27DJJOHNSON & JOHNSON : Prescription Unit List Prices Rose 8.5% Last Year
02/27 FTSE ends higher on some positive earnings, insurers slip
02/27DJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
More sector news : Generic Pharmaceuticals
News from SeekingAlpha
01/23 Bristol Catches A Break At Last
2016 Opdivo's price halved in Japan
2016 Bristol's Bid To Get Ahead In Head And Neck
2016 A European Biotech Stock Basket For 2016 - Update
Advertisement
Financials ( JPY)
Sales 2017 250 398 M
EBIT 2017 -
Net income 2017 53 292 M
Finance 2017 124 853 M
Yield 2017 1,68%
P/E ratio 2017 25,09
P/E ratio 2018 26,97
EV / Sales 2017 5,41x
EV / Sales 2018 5,20x
Capitalization 1 479 870 M
More Financials
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Full-screen chart
Technical analysis trends ONO PHARMACEUTICA...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 3 053  JPY
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Shozo Matsuoka Executive Officer & Manager-Medical Affairs
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ONO PHARMACEUTICAL CO...-2.17%13 192
OTSUKA HOLDINGS CO LTD0.94%25 658
SUN PHARMACEUTICAL IND..7.06%24 294
ASPEN PHARMACARE HOLDI..1.33%10 094
SHANGHAI FOSUN PHARMAC..13.01%9 098
TAISHO PHARMACEUTICAL ..-5.77%7 360
More Results